HONG KONG, Aug. 11, 2016 /PRNewswire/ -- Amgen, one of the world's leading biotechnology companies, has officially launched its new commercial office in Hong Kong in order to make its innovative medicines available to patients suffering from serious illnesses in the region.
Amgen's entry into Hong Kong and Macau will enhance the exchange of scientific ideas, foster more research collaborations and bring innovative therapies for grievous illnesses to local patients. For Amgen, it is an important step in the Company's global expansion efforts. The Company's Japan Asia Pacific (JAPAC) regional headquarters are also based at its One Island East offices, Taikoo Place, Hong Kong.
Amgen strives to serve patients by transforming the promise of science and biotechnology into therapies that have the power to restore health or save lives. The Company is focused on delivering its portfolio of approved medicines and its robust, late-stage pipeline of potential new innovative and biosimilar medicines to patients around the world.
"In 2007, Amgen opened a clinical development hub in Hong Kong with fewer than ten people. Today, we are delighted to launch our Hong Kong/Macau commercial office. We expect to employ more than 80 people by the end of the year in Hong Kong, serving patients locally and in the rest of the JAPAC region," said Penny Wan, regional vice president and general manager of Amgen's JAPAC region.
Amgen's initial priorities in Hong Kong and Macau will include:
• Working with healthcare providers and payers to ensure the patients who can benefit from Amgen's approved medicines can access them; • Advancing its clinical pipeline, which includes treatments for bone disease, cardiovascular, hematology / oncology, nephrology, inflammation, neuroscience and biosimilar medicines; • Being an active member in the local biotechnology industry to encourage mutual growth while contributing to the ongoing creation of an environment where the industry can thrive in Hong Kong and Macau.
The company has recently appointed Eric Ng as general manager of the Amgen South East Asia, Hong Kong and India region, and KK Tong as country director of the Amgen Hong Kong. Both of them have more than 20 years' experience in the healthcare and pharmaceutical industry across broad geographies and business areas.
"We're very pleased to have established this commercial office in Hong Kong and we look forward to growing our team here," said KK Tong. "As a biotechnology pioneer, we hope to help the advancement and growth of the biotechnology community in Hong Kong and Macau."
Amgen recently reacquired rights to three of its innovative medicines in 48 markets around the world, and is now the market authorization holder for Prolia® (denosumab), XGEVA® (denosumab), Vectibix® (panitumumab), Neulastim® (pegfilgrastim), and Neupogen® (filgrastim) in Hong Kong/Macau. Additionally, Amgen has received approval for Repatha® (evolocumab) from the Hong Kong Department of Health.
A worldwide leader in biologics manufacturing, Amgen has an outstanding track record of delivering high-quality medicines to patients who need them. The Company is headquartered in Thousand Oaks, Calif., is focused on expanding in the Asia Pacific region, and today has operations in more than 100 markets around the world, including Australia/New Zealand, mainland China, Hong Kong/Macau, India, Japan, South Korea, Singapore, Taiwan and Thailand.
About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit www.amgen.com.
Amgen's entry into Hong Kong and Macau will enhance the exchange of scientific ideas, foster more research collaborations and bring innovative therapies for grievous illnesses to local patients. For Amgen, it is an important step in the Company's global expansion efforts. The Company's Japan Asia Pacific (JAPAC) regional headquarters are also based at its One Island East offices, Taikoo Place, Hong Kong.
Amgen strives to serve patients by transforming the promise of science and biotechnology into therapies that have the power to restore health or save lives. The Company is focused on delivering its portfolio of approved medicines and its robust, late-stage pipeline of potential new innovative and biosimilar medicines to patients around the world.
"In 2007, Amgen opened a clinical development hub in Hong Kong with fewer than ten people. Today, we are delighted to launch our Hong Kong/Macau commercial office. We expect to employ more than 80 people by the end of the year in Hong Kong, serving patients locally and in the rest of the JAPAC region," said Penny Wan, regional vice president and general manager of Amgen's JAPAC region.
Amgen's initial priorities in Hong Kong and Macau will include:
• Working with healthcare providers and payers to ensure the patients who can benefit from Amgen's approved medicines can access them; • Advancing its clinical pipeline, which includes treatments for bone disease, cardiovascular, hematology / oncology, nephrology, inflammation, neuroscience and biosimilar medicines; • Being an active member in the local biotechnology industry to encourage mutual growth while contributing to the ongoing creation of an environment where the industry can thrive in Hong Kong and Macau.
The company has recently appointed Eric Ng as general manager of the Amgen South East Asia, Hong Kong and India region, and KK Tong as country director of the Amgen Hong Kong. Both of them have more than 20 years' experience in the healthcare and pharmaceutical industry across broad geographies and business areas.
"We're very pleased to have established this commercial office in Hong Kong and we look forward to growing our team here," said KK Tong. "As a biotechnology pioneer, we hope to help the advancement and growth of the biotechnology community in Hong Kong and Macau."
Amgen recently reacquired rights to three of its innovative medicines in 48 markets around the world, and is now the market authorization holder for Prolia® (denosumab), XGEVA® (denosumab), Vectibix® (panitumumab), Neulastim® (pegfilgrastim), and Neupogen® (filgrastim) in Hong Kong/Macau. Additionally, Amgen has received approval for Repatha® (evolocumab) from the Hong Kong Department of Health.
A worldwide leader in biologics manufacturing, Amgen has an outstanding track record of delivering high-quality medicines to patients who need them. The Company is headquartered in Thousand Oaks, Calif., is focused on expanding in the Asia Pacific region, and today has operations in more than 100 markets around the world, including Australia/New Zealand, mainland China, Hong Kong/Macau, India, Japan, South Korea, Singapore, Taiwan and Thailand.
About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit www.amgen.com.
